ENGINEERING MEDICINES TO IMPROVE PATIENT CARE Investors News Releases Year None2022202120202019201820172016 May 12, 2022 Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates May 3, 2022 Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022 April 6, 2022 Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14 April 4, 2022 Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital March 21, 2022 Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease March 14, 2022 Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15 March 10, 2022 Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates March 3, 2022 Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022 February 14, 2022 Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18 January 31, 2022 Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 11
Year None2022202120202019201820172016 May 12, 2022 Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates May 3, 2022 Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022 April 6, 2022 Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14 April 4, 2022 Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital March 21, 2022 Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease March 14, 2022 Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15 March 10, 2022 Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates March 3, 2022 Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022 February 14, 2022 Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18 January 31, 2022 Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 11
May 12, 2022 Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates
May 3, 2022 Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022
April 6, 2022 Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14
April 4, 2022 Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital
March 21, 2022 Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
March 14, 2022 Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15
March 10, 2022 Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates
March 3, 2022 Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022
February 14, 2022 Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18
January 31, 2022 Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease